Clinical experiment designed to assess clinical efficacy targeting PSP in human. Primary outcome: Validate PSP and CBS Biomarker Validation Study
Description
PSP and CBS Biomarker Validation Study
Background and Rationale
Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS) are devastating 4R-tauopathies that present with overlapping clinical features, making early and accurate diagnosis extremely challenging. Current diagnostic approaches rely primarily on clinical criteria, often leading to misdiagnosis rates exceeding 30% and delayed therapeutic interventions. The lack of validated biomarkers significantly hampers clinical trial design, patient stratification, and therapeutic development. This multicenter, longitudinal biomarker validation study aims to establish a comprehensive multimodal biomarker panel incorporating cerebrospinal fluid (CSF), plasma, and neuroimaging markers for PSP and CBS. The study will employ a prospective cohort design comparing biomarker profiles across PSP patients, CBS patients, Parkinson's disease controls, and healthy controls over 24 months. Primary measurements include CSF tau isoforms (4R-tau, phosphorylated tau at multiple epitopes), neurofilament light chain, and novel candidate markers identified through proteomics....
PSP and CBS Biomarker Validation Study
Background and Rationale
Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS) are devastating 4R-tauopathies that present with overlapping clinical features, making early and accurate diagnosis extremely challenging. Current diagnostic approaches rely primarily on clinical criteria, often leading to misdiagnosis rates exceeding 30% and delayed therapeutic interventions. The lack of validated biomarkers significantly hampers clinical trial design, patient stratification, and therapeutic development. This multicenter, longitudinal biomarker validation study aims to establish a comprehensive multimodal biomarker panel incorporating cerebrospinal fluid (CSF), plasma, and neuroimaging markers for PSP and CBS. The study will employ a prospective cohort design comparing biomarker profiles across PSP patients, CBS patients, Parkinson's disease controls, and healthy controls over 24 months. Primary measurements include CSF tau isoforms (4R-tau, phosphorylated tau at multiple epitopes), neurofilament light chain, and novel candidate markers identified through proteomics. Plasma biomarkers will include tau species detectable by ultra-sensitive assays, glial fibrillary acidic protein, and inflammatory cytokines. Advanced neuroimaging will encompass structural MRI with automated volumetric analysis, diffusion tensor imaging, and tau-PET using second-generation tracers. The innovation lies in integrating multiple biomarker modalities with machine learning algorithms to develop predictive models for diagnosis, progression, and treatment response. This approach addresses critical unmet needs in tauopathy research by providing tools for earlier diagnosis, improved clinical trial design, and personalized therapeutic monitoring, ultimately accelerating the development of disease-modifying treatments for these rapidly progressive neurodegenerative disorders.
This experiment directly tests predictions arising from the following hypotheses:
TREM2-mediated microglial tau clearance enhancement
LRP1-Dependent Tau Uptake Disruption
Tau-Independent Microtubule Stabilization via MAP6 Enhancement
Noradrenergic-Tau Propagation Blockade
HSP90-Tau Disaggregation Complex Enhancement
Experimental Protocol
Phase 1 (Months 1-6): Recruit 300 participants across 5 centers: 75 PSP patients (MDS-PSP criteria), 75 CBS patients (Armstrong criteria), 75 PD controls, 75 healthy controls. Obtain informed consent, medical history, and baseline assessments including MDS-UPDRS, PSP Rating Scale, and cognitive batteries. Phase 2 (Months 1-24): Collect biospecimens at baseline, 6, 12, 18, and 24 months. CSF collection (20mL) via lumbar puncture with immediate processing and storage at -80°C. Plasma collection (50mL) with EDTA tubes, centrifugation within 2 hours, and aliquoting. Perform neuroimaging at baseline, 12, and 24 months using standardized protocols: 3T MRI with T1-weighted, FLAIR, DTI sequences, and tau-PET with [18F]MK-6240 tracer. Phase 3 (Months 6-30): Biomarker analysis using established and novel assays. CSF analysis via Simoa and ELISA for tau isoforms (AT8, AT180, AT270 phospho-epitopes), NFL, GFAP, and targeted proteomics panel. Plasma analysis using ultra-sensitive Simoa assays for p-tau217, p-tau231, NFL, and GFAP. Neuroimaging analysis using automated segmentation software for volumetric measurements and DTI metrics. Phase 4 (Months 24-36): Statistical analysis and model development. Use logistic regression and machine learning algorithms (random forest, support vector machine) to develop diagnostic and prognostic models. Validate models using cross-validation and independent test sets.
Expected Outcomes
CSF 4R-tau levels will be significantly elevated in PSP patients compared to controls, with mean concentrations 2.5-fold higher (p<0.001) and area under ROC curve >0.85 for PSP diagnosis
Plasma p-tau217 will demonstrate moderate diagnostic accuracy with 1.8-fold elevation in PSP/CBS versus controls (p<0.01) and correlation coefficient r>0.6 with CSF markers
Multimodal biomarker panel combining CSF, plasma, and imaging markers will achieve diagnostic accuracy >90% for PSP and >85% for CBS versus controls and other neurodegenerative diseases
Neurofilament light chain levels will correlate with disease severity scores (r>0.5, p<0.001) and predict clinical progression with hazard ratio >2.0 for rapid progressors
Neuroimaging metrics including midbrain atrophy and superior cerebellar peduncle changes will show effect sizes >0.8 for PSP discrimination and annual progression rates 15-25% greater than controls
Machine learning models incorporating all biomarker modalities will demonstrate superior performance to individual markers, with sensitivity >85% and specificity >90% for early-stage disease detection
Success Criteria
• Achieve primary endpoint of diagnostic accuracy ≥85% for PSP and ≥80% for CBS using the multimodal biomarker panel compared to clinical diagnosis confirmed by 24-month follow-up
• Demonstrate statistically significant differences (p<0.01) in at least 3 core biomarkers between disease groups and controls with effect sizes >0.5
• Successfully recruit and retain ≥85% of target sample size (255/300 participants) through 24-month follow-up period across all study sites
• Establish biomarker cut-off values with positive predictive value ≥75% and negative predictive value ≥80% for clinical trial enrichment applications
• Validate progression biomarkers showing correlation ≥0.4 with clinical rating scales and ability to detect ≥30% reduction in required sample sizes for future clinical trials
• Generate reproducible assay protocols with inter-site coefficient of variation <15% for CSF markers and <20% for plasma markers across participating centers
Phase 1 (Months 1-6): Recruit 300 participants across 5 centers: 75 PSP patients (MDS-PSP criteria), 75 CBS patients (Armstrong criteria), 75 PD controls, 75 healthy controls. Obtain informed consent, medical history, and baseline assessments including MDS-UPDRS, PSP Rating Scale, and cognitive batteries. Phase 2 (Months 1-24): Collect biospecimens at baseline, 6, 12, 18, and 24 months. CSF collection (20mL) via lumbar puncture with immediate processing and storage at -80°C. Plasma collection (50mL) with EDTA tubes, centrifugation within 2 hours, and aliquoting. Perform neuroimaging at baseline, 12, and 24 months using standardized protocols: 3T MRI with T1-weighted, FLAIR, DTI sequences, and tau-PET with [18F]MK-6240 tracer.
...
Phase 1 (Months 1-6): Recruit 300 participants across 5 centers: 75 PSP patients (MDS-PSP criteria), 75 CBS patients (Armstrong criteria), 75 PD controls, 75 healthy controls. Obtain informed consent, medical history, and baseline assessments including MDS-UPDRS, PSP Rating Scale, and cognitive batteries. Phase 2 (Months 1-24): Collect biospecimens at baseline, 6, 12, 18, and 24 months. CSF collection (20mL) via lumbar puncture with immediate processing and storage at -80°C. Plasma collection (50mL) with EDTA tubes, centrifugation within 2 hours, and aliquoting. Perform neuroimaging at baseline, 12, and 24 months using standardized protocols: 3T MRI with T1-weighted, FLAIR, DTI sequences, and tau-PET with [18F]MK-6240 tracer. Phase 3 (Months 6-30): Biomarker analysis using established and novel assays. CSF analysis via Simoa and ELISA for tau isoforms (AT8, AT180, AT270 phospho-epitopes), NFL, GFAP, and targeted proteomics panel. Plasma analysis using ultra-sensitive Simoa assays for p-tau217, p-tau231, NFL, and GFAP. Neuroimaging analysis using automated segmentation software for volumetric measurements and DTI metrics. Phase 4 (Months 24-36): Statistical analysis and model development. Use logistic regression and machine learning algorithms (random forest, support vector machine) to develop diagnostic and prognostic models. Validate models using cross-validation and independent test sets.
Expected Outcomes
CSF 4R-tau levels will be significantly elevated in PSP patients compared to controls, with mean concentrations 2.5-fold higher (p<0.001) and area under ROC curve >0.85 for PSP diagnosis
Plasma p-tau217 will demonstrate moderate diagnostic accuracy with 1.8-fold elevation in PSP/CBS versus controls (p<0.01) and correlation coefficient r>0.6 with CSF markers
Multimodal biomarker panel combining CSF, plasma, and imaging markers will achieve diagnostic accuracy >90% for PSP and >85% for CBS versus controls and other neurodegenerative diseases
Neurofilament light chain levels will correlate
...
CSF 4R-tau levels will be significantly elevated in PSP patients compared to controls, with mean concentrations 2.5-fold higher (p<0.001) and area under ROC curve >0.85 for PSP diagnosis
Plasma p-tau217 will demonstrate moderate diagnostic accuracy with 1.8-fold elevation in PSP/CBS versus controls (p<0.01) and correlation coefficient r>0.6 with CSF markers
Multimodal biomarker panel combining CSF, plasma, and imaging markers will achieve diagnostic accuracy >90% for PSP and >85% for CBS versus controls and other neurodegenerative diseases
Neurofilament light chain levels will correlate with disease severity scores (r>0.5, p<0.001) and predict clinical progression with hazard ratio >2.0 for rapid progressors
Neuroimaging metrics including midbrain atrophy and superior cerebellar peduncle changes will show effect sizes >0.8 for PSP discrimination and annual progression rates 15-25% greater than controls
Machine learning models incorporating all biomarker modalities will demonstrate superior performance to individual markers, with sensitivity >85% and specificity >90% for early-stage disease detection
Success Criteria
• Achieve primary endpoint of diagnostic accuracy ≥85% for PSP and ≥80% for CBS using the multimodal biomarker panel compared to clinical diagnosis confirmed by 24-month follow-up
• Demonstrate statistically significant differences (p<0.01) in at least 3 core biomarkers between disease groups and controls with effect sizes >0.5
• Successfully recruit and retain ≥85% of target sample size (255/300 participants) through 24-month follow-up period across all study sites
• Establish biomarker cut-off values with positive predictive value ≥75% and negative predictive value ≥80% for clinical t
...
• Achieve primary endpoint of diagnostic accuracy ≥85% for PSP and ≥80% for CBS using the multimodal biomarker panel compared to clinical diagnosis confirmed by 24-month follow-up
• Demonstrate statistically significant differences (p<0.01) in at least 3 core biomarkers between disease groups and controls with effect sizes >0.5
• Successfully recruit and retain ≥85% of target sample size (255/300 participants) through 24-month follow-up period across all study sites
• Establish biomarker cut-off values with positive predictive value ≥75% and negative predictive value ≥80% for clinical trial enrichment applications
• Validate progression biomarkers showing correlation ≥0.4 with clinical rating scales and ability to detect ≥30% reduction in required sample sizes for future clinical trials
• Generate reproducible assay protocols with inter-site coefficient of variation <15% for CSF markers and <20% for plasma markers across participating centers